Brain scan study aims to predict drug success in recurrent glioblastoma
NCT ID NCT04566185
First seen Dec 16, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This study looked at whether special brain scans (PET and CT perfusion) can predict how well the drug bevacizumab works in people with a returning brain tumor called glioblastoma. Fourteen patients were enrolled. The goal was to see if these scans could tell doctors early on who would respond to treatment, rather than testing the drug itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nimes
Nîmes, 30029, France
Conditions
Explore the condition pages connected to this study.